Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study

Abstract

BackgroundBased on the 24-week, prospective, non-interventional, observational study, A1chieve®, we investigated how health-related quality of life (HRQoL) changed, and the predictors of such changes, in Chinese people with type 2 diabetes mellitus (T2DM) after starting with, or switching to, biphasic insulin aspart 30 (BIAsp 30).MethodsIn total, 8,578 people with T2DM starting treatment with, or switching to, BIAsp 30 were recruited from 130 urban hospitals in China. HRQoL was assessed at baseline and 24 weeks using the EuroQol-5 dimensions (EQ-5D) questionnaire. Descriptive statistics, paired t-test, and chi-square test were conducted and the linear ordinary least squares regression model was used to determine predictors for changes in EQ-5D score.ResultsHaemoglobin A1c (HbA1c) decreased from 9.5% to 7.0% after 24 weeks. The reported HRQoL measured by the EQ-5D visual analogue scale score increased by 6.2 (p < 0.001) from 75.8 to 82.0, and EQ-5D index score increased by 0.018 (p < 0.001) from 0.875 to 0.893 for the cohort over 24 weeks. The percentage of patients reporting no problems in the mobility, pain/discomfort, and anxiety/depression dimensions of EQ-5D increased significantly (p < 0.001) from 88.4% to 91.4%, 77.3% to 82.8%, and 74.2% to 77.1%, respectively. Patients with higher HbA1c levels at baseline, major hypoglycaemia or micro-complications exhibited significantly larger changes in EQ-5D scores than those with lower baseline HbA1c levels, without major hypoglycaemia or micro-complications after controlling for demographics and other baseline characteristics.ConclusionsBIAsp 30 treatment was associated with improved glycaemic control and HRQoL in T2DM patients in China. Patients with worse health conditions were more likely to experience larger improvements in HRQoL than those with better health conditions.Trial registrationClinicalTrials.gov, NCT00869908.Electronic supplementary materialThe online version of this article (doi:10.1186/s12955-014-0137-9) contains supplementary material, which is available to authorized users.

Association between insulin therapy and quality of life in diabetes

“…Also, patients switched from human insulins to insulin analogues reported improvement in QoL [20]. Similar results were obtained in a Chinese observational study evaluating the effect of initiation of biphasic insulin aspart 30 in 6,612 insulin naïve patients, or switching to this insulin analogue in 1,966 already insulin-treated subjects [21]. In a Dutch prospective cohort study, initiation of insulin glargine in both insulin-naïve as well as in insulin-treated patients with type 2 diabetes, resulted in improvement in QoL [22].…”

Fasting plasma glucose and lipid profiles of diabetic patients improve with aerobic exercise training

“…In addition, positive changes were also evident in a three-week walking programme reported in the study of GoldhaberFiebert et al although insignificantly small. 48,49 The percentage decline in LDL-C (11.9%) observed in this study is greater than the value in the meta-analysis conducted by Kelly and Kelly which indicated a significant reduction by 5% for LDL-C. 50 The improvement in TC, T, HDL-C-C and LDL-C exhibits clear evidence of reduction in atherogenic traits of risk factors 51,52 and better quality of life [53][54][55] of the sample studied. Authors observed that there are variations in the findings associated with this study in literature which are attributed to intensity, duration and frequency of exercise trainings and sample sizes.…”

A randomized, open‐label, multicentre, parallel‐controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study

“…26 In the present study, patients treated with BIAsp 30 plus metformin had significantly higher patient satisfaction scores than patients receiving BIAsp 30 alone. 26 In the present study, patients treated with BIAsp 30 plus metformin had significantly higher patient satisfaction scores than patients receiving BIAsp 30 alone.…”

“…A large observational study in China found that premixed insulin improved quality of life for type 2 diabetes patients. 26 In the present study, patients treated with BIAsp 30 plus metformin had significantly higher patient satisfaction scores than patients receiving BIAsp 30 alone. Given that weight gain was lower in patients receiving BIAsp 30 plus metformin, it is possible that this contributed to the higher satisfaction level in that group.…”